What Makes Revvity (RVTY) a New Buy Stock

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Sep 1, 2026

Is the Options Market Predicting a Spike in Revvity Stock?

Investors need to pay close attention to RVTY stock based on the movements in the options market lately.

Zacks Investment Research • Aug 24, 2026

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

Zacks Investment Research • Aug 13, 2026

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird's 2026 Global Healthcare Conference Tuesday, September.

Business Wire • Aug 11, 2026

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an.

Business Wire • Aug 10, 2026

Revvity Q2 Earnings Call Highlights

Revvity NYSE: RVTY reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows.

MarketBeat • Aug 9, 2026

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Medical equipment maker ​Revvity raised its annual profit and revenue forecasts on ‌Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-development tools and diagnostic testing products.

Reuters • Aug 4, 2026

Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Revvity Announces Financial Results for the Second Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related.

Business Wire • Aug 4, 2026

Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates

Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago.

Zacks Investment Research • Aug 4, 2026